Table 1.

Adjuvant tools for risk stratification at the time of endoscopy.

Tool	Model	Biomarkers	Sensitivity/specificity for predicting neoplastic progression to HGD/EAC	Costs
p53	IHC staining		NDBE/LGD cohort: Sensitivity 49%, Specificity 86% (18)	$
TissueCypher	IF of molecular biomarkers + morphologic factors (nuclear size, shape, DNA amount)	p53, p16, AMACR, HER-2) CD68, COX2, HIF1 alpha, CD45RO	Mixed NDBE/IND/LGD cohort: high-intermediate risk class 55%/82% (29)	$$$
Wats3D	Extensive Barrett's segment sampling + computer-aided analysis		2.1 % incremental yield in a mixed cohort with NDBE and all variants of dysplasia (34)	$$